Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAMA BALARAMAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1396709424
CMS profile
154127
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$17,030.22

196 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,462.00 5
Food and Beverage $3,520.65 173
Honoraria $3,000.00 2
Long term medical supply or device loan $1,014.85 11
Travel and Lodging $909.77 2
Education $122.95 3

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $3,302.32 12
Fresenius Kabi USA, LLC $2,550.00 1
Pharmacosmos Therapeutics Inc. $2,409.77 3
MorphoSys, US Inc. $1,514.33 4
E.R. Squibb & Sons, L.L.C. $1,510.76 6
G1 Therapeutics, Inc. $1,500.00 1
Novartis Pharmaceuticals Corporation $1,047.47 13
Amgen Inc. $288.52 10
Janssen Biotech, Inc. $220.02 11
Octapharma USA, Inc. $164.90 1
Seagen Inc. $147.19 8
PFIZER INC. $140.20 8
Daiichi Sankyo Inc. $135.90 9
Genentech USA, Inc. $132.79 9
Stryker Corporation $124.78 1
Lilly USA, LLC $118.56 7
Bayer HealthCare Pharmaceuticals Inc. $116.11 5
Incyte Corporation $97.11 5
GlaxoSmithKline, LLC. $95.71 5
Pharmacyclics LLC, An AbbVie Company $94.74 5
GENZYME CORPORATION $92.03 5
Merck Sharp & Dohme Corporation $87.30 5
Kite Pharma, Inc. $83.87 4
JAZZ PHARMACEUTICALS INC. $80.88 4
Astellas Pharma US Inc $73.89 5
BeiGene USA, Inc. $70.73 3
TG THERAPEUTICS, INC. $64.71 1
Rigel Pharmaceuticals, Inc. $60.78 2
Boehringer Ingelheim Pharmaceuticals, Inc. $60.36 3
Heron Therapeutics, Inc. $54.74 4
Foundation Medicine, Inc. $53.86 2
Servier Pharmaceuticals LLC $53.40 3
PUMA BIOTECHNOLOGY, INC. $49.68 3
Taiho Oncology, Inc. $44.94 2
Eisai Inc. $43.82 3
Karyopharm Therapeutics Inc. $39.49 3
Takeda Pharmaceuticals U.S.A., Inc. $33.94 2
Global Blood Therapeutics, Inc. $29.87 2
ADC Therapeutics America, Inc. $20.59 1
Dova Pharmaceuticals $18.07 1
Kyowa Kirin, Inc. $17.61 1
Blueprint Medicines Corporation $17.11 1
Ipsen Biopharmaceuticals, Inc $16.81 1
Alnylam Pharmaceuticals Inc. $16.69 1
Exelixis Inc. $16.29 1
Regeneron Healthcare Solutions, Inc. $16.22 1
Blue Earth Diagnostics Limited $15.41 1
Epizyme, Inc., $13.53 1
Celgene Corporation $13.40 1
ARRAY BIOPHARMA INC $13.14 1
AbbVie Inc. $11.99 1
Gilead Sciences, Inc. $11.92 1
CSL Behring $11.61 1
GE HEALTHCARE $10.36 1

Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAMA BALARAMAN

NPI 1396709424 · CMS profile ID 154127

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396709424?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAMA BALARAMAN, NPI 1396709424, CMS profile ID 154127. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396709424?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RAMA BALARAMAN, NPI 1396709424, CMS profile ID 154127. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396709424?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RAMA BALARAMAN, NPI 1396709424, CMS profile ID 154127, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1396709424?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

196 matching records · $17,030.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 196 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 196.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $18.2008/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833481185 CMS
AstraZeneca Pharmaceuticals LP $1,388.0008/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829472391 CMS
Lilly USA, LLC $14.3907/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818690159 CMS
AstraZeneca Pharmaceuticals LP $1,665.0007/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829359185 CMS
Heron Therapeutics, Inc. $10.3507/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781448935 CMS
GENZYME CORPORATION $17.7207/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843514211 CMS
Daiichi Sankyo Inc. $20.1807/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836305841 CMS
Daiichi Sankyo Inc. $25.4807/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836308053 CMS
Karyopharm Therapeutics Inc. $11.1407/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845788167 CMS
Amgen Inc. $17.4807/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826413635 CMS
Genentech USA, Inc. $14.1407/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835964921 CMS
Novartis Pharmaceuticals Corporation $19.2807/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812598571 CMS
Novartis Pharmaceuticals Corporation $13.3407/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812598573 CMS
Astellas Pharma US Inc $14.5407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821254157 CMS
Genentech USA, Inc. $12.4307/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835964933 CMS
Janssen Biotech, Inc. $19.1807/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788191077 CMS
PFIZER INC. $11.8707/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833542191 CMS
Regeneron Healthcare Solutions, Inc. $16.2207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809557407 CMS
Seagen Inc. $12.3206/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832174027 CMS
Amgen Inc. $23.6706/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826413627 CMS
Lilly USA, LLC $19.2406/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818719709 CMS
GlaxoSmithKline, LLC. $14.2006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803073969 CMS
Janssen Biotech, Inc. $19.3506/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788191073 CMS
Genentech USA, Inc. $21.6306/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835964915 CMS
Genentech USA, Inc. $12.2406/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835964917 CMS
Novartis Pharmaceuticals Corporation $99.7006/16/2021 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812598583 CMS
AbbVie Inc. $11.9906/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793970159 CMS
Janssen Biotech, Inc. $19.2806/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788191079 CMS
Lilly USA, LLC $18.9006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818719711 CMS
Seagen Inc. $18.1206/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832174003 CMS
JAZZ PHARMACEUTICALS INC. $19.8606/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845594295 CMS
Kite Pharma, Inc. $32.4506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844410503 CMS
Amgen Inc. $22.8006/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826413631 CMS
Octapharma USA, Inc. $164.9006/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812973231 CMS
Amgen Inc. $99.9906/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826538213 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845870731 CMS
AstraZeneca Pharmaceuticals LP $17.8605/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830167189 CMS
Fresenius Kabi USA, LLC $2,550.0005/20/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845609825 CMS
Lilly USA, LLC $9.8105/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818710781 CMS
Merck Sharp & Dohme Corporation $11.6705/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848561367 CMS
E.R. Squibb & Sons, L.L.C. $21.5605/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783643349 CMS
Servier Pharmaceuticals LLC $20.2605/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852922567 CMS
Lilly USA, LLC $21.3205/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818732619 CMS
Novartis Pharmaceuticals Corporation $99.7005/14/2021 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812598581 CMS
Taiho Oncology, Inc. $22.4905/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843380603 CMS
BeiGene USA, Inc. $39.4805/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846699675 CMS
Exelixis Inc. $16.2905/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838868965 CMS
Janssen Biotech, Inc. $27.0505/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788191065 CMS
Genentech USA, Inc. $14.4005/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835964923 CMS
ARRAY BIOPHARMA INC $13.1405/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833183667 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,610.31 190
PY2020 $20,057.76 104
PY2021 $17,030.22 196
PY2022 $11,349.50 199
PY2023 $14,864.81 165
PY2024 $5,716.54 164
PY2025 $15,531.08 149

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,663.72 2
PY2025 Principal investigator $733,990.68 59
PY2024 Principal investigator $505,687.74 25
PY2023 Recipient $1,082.54 6
PY2023 Principal investigator $774,093.61 33
PY2022 Principal investigator $1,208,600.24 8
PY2021 Principal investigator $2,186,697.99 10
PY2020 Principal investigator $1,227,327.22 12
PY2019 Principal investigator $610,055.01 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $20,955.56 11/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (SEZanne) No dispute reported 06/30/2026 1202523093
Principal investigator 1 BeOne Medicines Ltd. $4,258.00 10/20/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329259
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 10/20/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329309
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 10/20/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190341591
Principal investigator 1 BeOne Medicines Ltd. $2,228.00 10/20/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190341615
Principal investigator 1 Genmab U.S., Inc. $1,437.75 10/14/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932592
Principal investigator 1 BeOne Medicines Ltd. $2,250.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327031
Principal investigator 1 BeOne Medicines Ltd. $3,000.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327055
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327065
Principal investigator 1 BeOne Medicines Ltd. $4,500.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327071
Principal investigator 1 BeOne Medicines Ltd. $1,800.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327085
Principal investigator 1 BeOne Medicines Ltd. $1,250.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327107
Principal investigator 1 BeOne Medicines Ltd. $23,100.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327221
Principal investigator 1 BeOne Medicines Ltd. $14,400.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327287
Principal investigator 1 BeOne Medicines Ltd. $6,245.00 09/24/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327053
Principal investigator 1 BeOne Medicines Ltd. $2,498.00 09/24/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327239
Principal investigator 1 Genmab U.S., Inc. $24,030.00 08/04/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932581
Principal investigator 1 BeOne Medicines Ltd. $3,510.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327037
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327049
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327093
Principal investigator 1 BeOne Medicines Ltd. $2,228.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327271
Principal investigator 1 BeOne Medicines Ltd. $4,258.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331779
Principal investigator 1 Genmab U.S., Inc. $26,400.00 07/25/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932585
Principal investigator 1 Genmab U.S., Inc. $24,030.00 07/25/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932588
Principal investigator 1 GlaxoSmithKline, LLC. $2,025.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150069
Principal investigator 1 GlaxoSmithKline, LLC. $4,050.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150074
Principal investigator 1 GlaxoSmithKline, LLC. $18,900.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150078
Principal investigator 1 GlaxoSmithKline, LLC. $2,430.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150082
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150088
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.50 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154944
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154948
Principal investigator 1 BeOne Medicines Ltd. $3,033.00 07/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327285
Principal investigator 1 Genmab U.S., Inc. $55,890.00 06/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932560
Principal investigator 1 Genmab U.S., Inc. $4,580.25 06/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932564
Principal investigator 1 Genmab U.S., Inc. $12,015.00 06/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932568
Principal investigator 1 Genmab U.S., Inc. $14,715.00 06/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932576
Principal investigator 1 Genmab U.S., Inc. $7,039.92 05/28/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932556
Principal investigator 1 BeiGene, Ltd. $3,498.00 05/16/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320700
Principal investigator 1 BeiGene, Ltd. $3,498.00 05/16/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325646
Principal investigator 1 BeiGene, Ltd. $8,100.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320792
Principal investigator 1 BeiGene, Ltd. $8,912.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322888
Principal investigator 1 BeiGene, Ltd. $10,125.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325040
Principal investigator 1 BeiGene, Ltd. $3,510.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325048
Principal investigator 1 BeiGene, Ltd. $11,140.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325604
Principal investigator 1 BeiGene, Ltd. $10,125.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325620
Principal investigator 1 BeiGene, Ltd. $8,100.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325634
Principal investigator 1 ABBVIE INC. $20,000.00 05/07/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202483349
Principal investigator 1 BeiGene, Ltd. $3,498.00 04/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325016
Principal investigator 1 Genmab U.S., Inc. $17,921.68 04/24/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932572
Principal investigator 1 Mirati Therapeutics, Inc. $887.50 04/02/2025 Non-covered Recipient Entity
Ocala Oncology Center, Pl
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236530873
Recipient Novartis Pharmaceuticals Corporation $1,355.30 04/01/2025 Covered Recipient Physician CLEE011A2207 No dispute reported 06/30/2026 1190292827
Principal investigator 1 AstraZeneca Pharmaceuticals LP $61,263.92 03/24/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185550183
Principal investigator 1 Genmab U.S., Inc. $28,300.00 03/20/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932552
Principal investigator 1 Merck Sharp & Dohme LLC $157,600.00 03/18/2025 Non-covered Recipient Entity
Ocala Oncology Center
An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232932637
Recipient GlaxoSmithKline, LLC. $308.42 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154952
Principal investigator 1 BeiGene, Ltd. $3,498.00 03/12/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190319988
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,300.00 02/25/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
Clinical trial to assess the efficacy and safety of an alternative dosing regimen of ribociclib in breast cancer No dispute reported 06/30/2026 1190310040
Principal investigator 1 BeiGene, Ltd. $3,498.00 02/21/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320018
Principal investigator 1 BeiGene, Ltd. $3,498.00 02/21/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324294
Principal investigator 1 Genmab U.S., Inc. $43,850.60 01/30/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932548
Principal investigator 1 BeiGene, Ltd. $3,498.00 01/29/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324634